Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes.

We are excited to announce that Takara Bio Europe AB will be supporting PanCryos’ efforts to develop a cell-based therapy for diabetes through the out-licensing of Takara Bio’s new clinical-grade hES cell line.

Read the full release: (lifesciencenewswire.com)